Based on the CytomX Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for CytomX Therapeutics Inc is USD 3.25 over the next 12 months. CytomX Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of CytomX Therapeutics Inc is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, CytomX Therapeutics Inc’s stock price was USD 0.53. CytomX Therapeutics Inc’s stock price has changed by +16.88% over the past week, -9.87% over the past month and -75.23% over the last year.
No recent analyst target price found for CytomX Therapeutics Inc
No recent average analyst rating found for CytomX Therapeutics Inc
Company Overview CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California. Read Less
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics r...Read More
Frequently Asked Questions About CytomX Therapeutics Inc (CTMX) Stock
Based on ratings from 1 analysts CytomX Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on CTMX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CTMX is USD 3.25 over the next 12 months. The maximum analyst target price is USD 3.25 while the minimum anlayst target price is USD 3.25.
CTMX stock's Price/Earning ratio is 1.20.
Our analysis grades CTMX stock's Price / Earning ratio at D+. This means that CTMX stock's Price/Earning ratio is above 32% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CTMX may be fairly valued for its sector
The last closing price of CTMX's stock was USD 0.53.
The most recent market capitalization for CTMX is USD 0.04B.
Based on targets from 1 analysts, the average taret price for CTMX is projected at USD 3.25 over the next 12 months.
This means that CTMX's stock price may go up by +510.33% over the next 12 months.
We can't find any ETFs which contains CytomX Therapeutics Inc's stock.
As per our most recent records CytomX Therapeutics Inc has 119 Employees.
CytomX Therapeutics Inc's registered address is 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from CytomX Therapeutics Inc's website at https://www.cytomx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About CytomX Therapeutics Inc (CTMX) Stock
Based on ratings from 1 analysts CytomX Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on CTMX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CTMX is USD 3.25 over the next 12 months. The maximum analyst target price is USD 3.25 while the minimum anlayst target price is USD 3.25.
CTMX stock's Price/Earning ratio is 1.20.
Our analysis grades CTMX stock's Price / Earning ratio at D+. This means that CTMX stock's Price/Earning ratio is above 32% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CTMX may be fairly valued for its sector
The last closing price of CTMX's stock was USD 0.53.
The most recent market capitalization for CTMX is USD 0.04B.
Based on targets from 1 analysts, the average taret price for CTMX is projected at USD 3.25 over the next 12 months.
This means that CTMX's stock price may go up by +510.33% over the next 12 months.
We can't find any ETFs which contains CytomX Therapeutics Inc's stock.
As per our most recent records CytomX Therapeutics Inc has 119 Employees.
CytomX Therapeutics Inc's registered address is 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from CytomX Therapeutics Inc's website at https://www.cytomx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CTMX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
